The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

GSK is buying Rapt Therapeutics for $2.2 billion, the companies said Tuesday. Rapt stock rocketed.

GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT ...

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

Researchers at DTU have patented a new invention that uses naturally produced substances from bifidobacteria in the gut to help lower the risk of allergies and asthma. Allergies and asthma are ...

Whereas natural tolerance rates are generally high for common allergens, such as eggs, milk, and wheat, allergies to other foods often persist beyond childhood. For instance, approximately 72.2% of ...

The mechanism underlying how seasonal allergies recur year after year with precise timing remains largely unknown. An international team led by Professor Rudolf Valenta has identified a specific type ...

Non-IgE-mediated allergies typically manifest with a delayed onset of symptoms, primarily affecting the gastrointestinal tract, although they may also involve the skin or lungs. Depending on which non ...

Maria Curotto de Lafaille’s lab was trying to make human plasma cells in a dish. These weren’t just run-of-the-mill cells, though. The team was vying for something specific: plasma cells that churn ...

It is estimated that around 10% of the US population has peanut allergies, a medical emergency that can be treated but not cured. Compared to those without allergies, these individuals are at a ...